Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients
Status:
Recruiting
Trial end date:
2021-06-19
Target enrollment:
Participant gender:
Summary
SARS-CoV-2 infection induces a hyperinflammatory syndrome, causing the acute respiratory
distress syndrome, massive lung cell destruction and, as a plausible sequelae, pulmonary
fibrosis in COVID-19 patients.
Current focus has been on the development of novel immunosuppressant therapies, in order to
control the cytokine storm in COVID-19 patients. Thus, the effect of steroids, intravenous
immunoglobulin, non-steroidal immunosuppressants, selective cytokine blockade, JAK/STAT
pathway inbhibition, and mesenchymal precursor cells have been evaluated. Based on the above
information, we propose COLLAGEN-POLYVINYLPYRROLIDONE (Distinctive name: FibroquelMR, active
substance: Collagen-polyvinylpyrrolidone, pharmaceutical form: intramuscular injectable
solution, with sanitary registration No. 201M95 SSA IV and SSA code: 010 000 3999) as a
potential drug for the downregulation of the cytokine storm. Polymerized type I collagen
reduces the expression of IL-1β, IL-8, TNF-alpha, TGF-β1, IL-17, Cox-1, leukocyte adhesion
molecules (ELAM-1, VCAM- 1 and ICAM-1), some other mediators of inflammation and increases
the levels of IL-10 and the number of regulatory T cells. In addition, it promotes the
mechanisms of inhibition of tissue fibrosis, without adverse effects in rheumatoid arthritis
and osteoarthritis.